297 related articles for article (PubMed ID: 15592580)
21. Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system.
Leussink VI; Stettner M; Warnke C; Hartung HP
J Peripher Nerv Syst; 2016 Jun; 21(2):85-7. PubMed ID: 26968589
[TBL] [Abstract][Full Text] [Related]
22. Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
Preiningerova JL; Baumhackl U; Csepany T; Czaplinski A; Deisenhammer F; Derfuss T; Fabjan TH; Fazekas F; Fuchs S; Havrdova E; Ledinek AH; Illes Z; Jazbec SS; Klimova E; Komoly S; Kurca E; Linnebank M; Lisy L; Mares J; Prochazkova L; Csilla R; Szilasiova J; Stourac P; Talab R; Turcani P; Vachova M; Vecsei L; Vodusek D; Zapletalova O; Berger T
CNS Neurosci Ther; 2013 May; 19(5):302-6. PubMed ID: 23607697
[TBL] [Abstract][Full Text] [Related]
23. 4-Aminopyridine and spinal cord injury: a review.
Hayes KC
Restor Neurol Neurosci; 1994 Jan; 6(4):259-70. PubMed ID: 21551756
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels.
Nashmi R; Fehlings MG
Brain Res Brain Res Rev; 2001 Dec; 38(1-2):165-91. PubMed ID: 11750932
[TBL] [Abstract][Full Text] [Related]
25. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
Morrow SA; Rosehart H; Johnson AM
Mult Scler Relat Disord; 2017 Jan; 11():4-9. PubMed ID: 28104253
[TBL] [Abstract][Full Text] [Related]
26. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension.
Smith KJ; Felts PA; John GR
Brain; 2000 Jan; 123 ( Pt 1)():171-84. PubMed ID: 10611131
[TBL] [Abstract][Full Text] [Related]
27. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
Vollmer T; Blight AR; Henney HR
Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
[TBL] [Abstract][Full Text] [Related]
28. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.
Schwid SR; Petrie MD; McDermott MP; Tierney DS; Mason DH; Goodman AD
Neurology; 1997 Apr; 48(4):817-21. PubMed ID: 9109861
[TBL] [Abstract][Full Text] [Related]
29. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
Judge SI; Bever CT
Pharmacol Ther; 2006 Jul; 111(1):224-59. PubMed ID: 16472864
[TBL] [Abstract][Full Text] [Related]
30. Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.
Fragoso YD; Adoni T; Alves-Leon SV; Apostolos-Pereira SL; Barreira AA; Brooks JB; Claudino R; Correa EC; Ferreira ML; Finkelsztejn A; Finkelsztejn J; da Gama PD; Goncalves MV; Guerreiro CT; da Cunha Matta AP; Marques VD; Rizo Morales R; Parolin MF; de Castro Ribeiro M; Ribeiro TA; Ruocco HH; Sato H; Scherpenhuijzen S; Siquineli F; de Carvalho Sousa NA; Varela DL; Tauil CB; Winckler TC
NeuroRehabilitation; 2016 Jun; 39(2):301-4. PubMed ID: 27372365
[TBL] [Abstract][Full Text] [Related]
31. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
Dunn J; Blight A
Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
[TBL] [Abstract][Full Text] [Related]
32. Fampridine Acorda Therapeutics.
Darlington C
Curr Opin Investig Drugs; 2000 Nov; 1(3):375-9. PubMed ID: 11249722
[TBL] [Abstract][Full Text] [Related]
33. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
34. Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.
Smith W; Swan S; Marbury T; Henney H
J Clin Pharmacol; 2010 Feb; 50(2):151-9. PubMed ID: 19966074
[TBL] [Abstract][Full Text] [Related]
35. Dalfampridine: a new agent for symptomatic management of multiple sclerosis.
McDonald S; Clements JN
Am J Health Syst Pharm; 2011 Dec; 68(24):2335-40. PubMed ID: 22135060
[TBL] [Abstract][Full Text] [Related]
36. Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Keune PM; Cocks AJ; Young WR; Burschka JM; Hansen S; Hofstadt-van Oy U; Oschmann P; Muenssinger J
BMC Neurol; 2015 Sep; 15():171. PubMed ID: 26400041
[TBL] [Abstract][Full Text] [Related]
37. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients.
Hansebout RR; Blight AR; Fawcett S; Reddy K
J Neurotrauma; 1993; 10(1):1-18. PubMed ID: 8320728
[TBL] [Abstract][Full Text] [Related]
38. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury.
Qiao J; Hayes KC; Hsieh JT; Potter PJ; Delaney GA
J Neurotrauma; 1997 Mar; 14(3):135-49. PubMed ID: 9104931
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Cardenas DD; Ditunno J; Graziani V; Jackson AB; Lammertse D; Potter P; Sipski M; Cohen R; Blight AR
Spinal Cord; 2007 Feb; 45(2):158-68. PubMed ID: 16773037
[TBL] [Abstract][Full Text] [Related]
40. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve.
Targ EF; Kocsis JD
Brain Res; 1985 Mar; 328(2):358-61. PubMed ID: 2985185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
